Hengrui Medicine: HR18034 for injection will start clinical trials soon

2020-08-07
|
Roy Li

Hengrui Medicine announced that the company and its subsidiaries have recently received the Notice of Drug Clinical Trial Approval issued by the State Food and Drug Administration for the HR18034 injection which will start clinical trials in the near future.


The HR18034 for injection is a long-acting local anesthetic, intended for postoperative analgesia.


At present, similar drugs are being developed overseas and are currently in clinical trials. There is no similar product on the market at home and abroad.


Up to now, the product has been invested a total of about 7.81 million yuan in research and development.


RELATED ARTICLES

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China
2020-09-02
|
Pharmaceutical , Medical care

Xuanzhu Biopharm closes RMB 800 mln Series A
2020-08-27
|
Pharmaceutical , PEVC

Anti-body R&D company Escugen closes Pre-A raising tens of millions in RMB
2020-08-27
|
PEVC , Biotech , Pharmaceutical

China's first COVID-19 vaccine produced by insect cells obtained clinical trial approval
2020-08-24
|
Pharmaceutical , Vaccine , Covid-19 , Biotech

Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice
2020-05-14
|
Pharmaceutical
China SDG